Literature DB >> 1606522

The potential use of monoclonal antibodies as therapeutic modalities in neonatal infection.

H R Hill1, L A Gonzales, D K Kelsey, H V Raff.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1606522     DOI: 10.1007/978-1-4612-0417-6_3

Source DB:  PubMed          Journal:  Clin Rev Allergy        ISSN: 0731-8235


× No keyword cloud information.
  26 in total

1.  Comparative protective activity of human monoclonal and hyperimmune polyclonal antibody against group B streptococci.

Authors:  H R Hill; L A Gonzales; W A Knappe; G W Fischer; D K Kelsey; H V Raff
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

Review 2.  Group B streptococcal disease: its importance in the developing world and prospect for prevention with vaccines.

Authors:  J A Walsh; S Hutchins
Journal:  Pediatr Infect Dis J       Date:  1989-05       Impact factor: 2.129

3.  Protective efficacy of IgM monoclonal antibodies in experimental group B streptococcal infection is a function of antibody avidity.

Authors:  S H Pincus; A O Shigeoka; A A Moe; L P Ewing; H R Hill
Journal:  J Immunol       Date:  1988-04-15       Impact factor: 5.422

4.  The effect of hybridoma antibody administration upon neutrophil kinetics during experimental type III group B streptococcal sepsis.

Authors:  R D Christensen; G Rothstein; H R Hill; S H Pincus
Journal:  Pediatr Res       Date:  1983-10       Impact factor: 3.756

Review 5.  Immunoglobulin therapy of neonatal group B streptococcal infections: an overview.

Authors:  G W Fischer
Journal:  Pediatr Infect Dis J       Date:  1988-05       Impact factor: 2.129

6.  Protective efficacy of hybridoma type-specific antibody against experimental infection with group-B Streptococcus.

Authors:  A O Shigeoka; S H Pincus; N S Rote; H R Hill
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

7.  Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence.

Authors:  V G Hemming; R T Hall; P G Rhodes; A O Shigeoka; H R Hill
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

8.  Blood-transfusion in group-B streptococcal sepsis.

Authors:  A O Shigeoka; R T Hall; H R Hill
Journal:  Lancet       Date:  1978-03-25       Impact factor: 79.321

9.  Fibronectin enhances the opsonic and protective activity of monoclonal and polyclonal antibody against group B streptococci.

Authors:  H R Hill; A O Shigeoka; N H Augustine; D Pritchard; J L Lundblad; R S Schwartz
Journal:  J Exp Med       Date:  1984-06-01       Impact factor: 14.307

10.  Protection of mice from experimental infection with type III group B Streptococcus using monoclonal antibodies.

Authors:  M L Egan; D G Pritchard; H C Dillon; B M Gray
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.